All In Biotech

Drug Trial Radar · NCT00005975

S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer

A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626

Last checked: Nov 20, 2026Latest source record: Nov 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Apr 1998

Primary completion

Sep 2001

Study completion Mar 2002

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jun 28, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
Who can join
Female only, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Megestrol may be effective in treating hot flashes following treatment for breast cancer. It is not yet known which regimen of megestrol is most effective for hot flashes. PURPOSE: Randomized phase III trial to compare the effectiveness of different doses of megestrol in treating hot flashes in patients who have undergone therapy for breast cancer.

Conditions

  • Breast Cancer
  • Hot Flashes

Interventions

  • Megestrol Acetate 20mg/dayDrug

    Double blinded Megestrol Acetate 20 mg/day

  • Megestrol Acetate 40 mg/dayDrug

    Double blinded Megestrol Acetate 40 mg/day

  • Megestrol Acetate Placebo 20 mg/dayDrug

    Megestrol Acetate Placebo 20 mg/day

  • Megestrol Acetate Placebo 40 mg/dayDrug

    Megestrol Acetate Placebo 40 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness and duration of the benefit of placebo and 2 dose levels of megestrol acetate in reduction of severe and/or frequent hot flashes in patients with history of adequate local and regional treatment of invasive breast cancerTime frame: 3, 6, and 9 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.